Drug-induced thrombocytopenia in the coronary care unit

Journal of Thrombosis and Thrombolysis

Volumn 10, Issue 2, 2000, Pages 155-167

  Patnode, N M ^a   Gandhi, P J ^b  

^a University of Massachusetts   (United States)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Cardiology; Drug induced; Thrombocytopenia

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; AMIODARONE; AMPHOTERICIN B; AMRINONE; ANTIBIOTIC AGENT; ARGATROBAN; CAPTOPRIL; CEFALOTIN; CHLOROTHIAZIDE; COTRIMOXAZOLE; DANAPAROID; DIGOXIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN G; LEPIRUDIN; PIPERACILLIN; PROCAINAMIDE; QUINIDINE; RECOMBINANT HIRUDIN; TAZOBACTAM; THIAZIDE DIURETIC AGENT; TICLOPIDINE; TIROFIBAN; UNINDEXED DRUG; VANCOMYCIN; WARFARIN;

BONE MARROW EXAMINATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY CARE UNIT; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BINDING; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG INHIBITION; DRUG MONITORING; DRUG POTENTIATION; HEART SURGERY; HUMAN; META ANALYSIS; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; THROMBOSIS; VASCULAR DISEASE;

EID: 0033764877     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018766610796     Document Type: Review

References (126)

1. Thrombocytopenia in intensive care patients: A comprehensive analysis of risk factors in 314 patients
2. Thrombocytopenia: Issues in diagnosis and therapy
3. Drug-induced thrombocytopenia: A systematic review of published case reports
4. Drug-induced hematologic disorders
5. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting
6. Thrombotic thrombocytopenic purpura associated with ticlopidine: A review of 60 cases
7. Ticlopidine and thrombotic thrombocytopenic purpura
8. Antithrombotic therapy in peripheral arterial occlusive disease
9. Thrombotic thrombocytopenic purpura after stenting and ticlopidine
10. Ticlopidine-induced thrombotic thrombocytopenic purpura
11. Thrombotic thrombocytopenic purpura associated with ticlopidine therapy
12. Thrombocytopenia and hepatitis complicating ticlopidine therapy
13. Ticlopidine and thrombocytopenia
14. Ticlopidine and fatal aplastic anemia in an elderly woman
15. Thrombotic thrombocytopenic purpura associated with ticlopidine use
16. Thrombotic thrombocytopenic purpura: A rare but potential life-threatening complication following ticlopidine administration
17. Thrombotic thrombocytopenic purpura caused by ticlopidine, successfully treated by plasmapheresis
18. Heparin-induced thrombocytopenia: Towards consensus
19. Clinical presentation of heparin-induced thrombocytopenia
20. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety
21. Introduction: Heparin-induced thrombocytopenia
22. Pathophysiology and laboratory testing of heparin-induced thrombocytopenia
23. Heparin-induced thrombocytopenia: Diagnosis and contemporary antithrombin management
24. Recombinant hirudin (Lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study
25. Newer strategies for the treatment of heparin-induced thrombocytopenia
26. Recombinant hirudin for parenteral anticoagulation in patients with heparin-induced thrombocytopenia
27. Limitations of conventional treatment options for heparin-induced thrombocytopenia
28. Anticoagulant-induced thrombosis
29. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease
30. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization
31. Effect of platelet glycoprotein IIb/IIIa blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atheroctomy (EPIC)
32. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy
33. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
34. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in myocardial infarction undergoing coronary angioplasty
35. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
36. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
37. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using Integrilin therapy (PURSUIT) trial experience
38. Acute profound thrombocytopenia following c7E3 Fab (abciximab) therapy: Case reports, review of the literature and implications for therapy
39. Abciximab-associated profound thrombocytopenia: Therapy with immunoglobulin and platelet transfusion
40. Acute profound thrombocytopenia after c7E3 therapy
41. Delayed profound thrombocytopenia after c7E3 Fab (abciximab) therapy
42. Coronary stenting and use of abciximab
43. Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors
44. Thrombocytopenic purpura due to allergy to quinidine
45. The mechanism of quinidine purpura
46. Observations on the thrombocytopenia due to hypersensitivity to quinidine
47. Thrombocytopenic purpura following quinidine therapy
48. Atypical secondary or symptomatic thrombocytopenic purpura developing with the use of quinidine sulfate
49. Immunoreactions involving platelets: Studies on the pathogenesis of thrombocytopenia in drug purpura using test doses of quinidine in sensitive individuals. Their implications in idiopathic thrombocytopenic purpura
50. Immunothrombocytopenic purpura due to quinidine
51. Thrombocytopenic purpura following quinidine
52. Quinidine as a cause of thrombocytopenic purpura
53. Quinidine-induced thrombocytopenia
54. Correlation of a quinidine-induced platelet-specific antibody with development of thrombocytopenia
55. Quinidine-induced thrombocytopenia with pulmonary hemorrhage
56. Thrombocytopenic purpura due to quinidine. Clinical studies
57. Immune hemolytic anemia and thrombocytopenia secondary to quinidine: In vitro studies of the quinidine-dependent red cell and platelet antibody
58. Severe leukopenia and thrombocytopenia secondary to quinidine
59. Quinidine-induced hepatitis and thrombocytopenia
60. Quinidine-induced immune thrombocytopenia
61. Quinidine-induced thrombocytopenia. A case report
62. Quinidine-induced leukopenia and thrombocytopenia with a drug dependent leukoagglutinin
63. Quinine-induced thrombocytopenia
64. Idiosyncratic drug-induced thrombocytopenia
65. Thrombocytopenia due to quinidine sensitivity
66. Thrombocytopenia during chlorthiazide treatment
67. Thrombocytopenia and purpura in patients receiving chlorthiazide and hydrochlorothiazide
68. Hydrochlorothiazide-induced thrombocytopenic purpura
69. Hydrochlorothiazide-dependent thrombocytopenia due to IgM antibody
70. Acute idiosyncratic reaction to hydrochlorothiazide ingestion
71. Rapid diagnosis of drug-induced thrombocytopenic purpura
72. Cimetidine-induced thrombocytopenia
73. Cimetidine and thrombocytopenia
74. Cimetidine-induced thrombocytopenia in a cirrhotic patient
75. Thrombocytopenia with cimetidine
76. Cimetidine-induced, immune-mediated leukopenia and thrombocytopenia
77. Cimetidine and hematological effects
78. Cimetidine and thrombocytopenia
79. Cimetidine-associated thrombocytopenia
80. Cimetidine and ranitidine may not cross-react to cause thrombocytopenia
81. Leukopenia and thrombocytopenia with cimetidine
82. Marrow suppression and intravenous cimetidine
83. Cimetidine-associated thrombocytopenia
84. Severe thrombocytopenia due to combined cimetidine and phenytoin therapy
85. Severe thrombocytopenia associated with phenytoin and cimetidine therapy
86. Thrombocytopenia associated with hypersensitivity to ranitidine: Possible cross reactivity with cimetidine
87. Thrombocytopenia, eosinophilia and ranitidine
88. Thrombocytopenia associated with ranitidine
89. Thrombocytopenia associated with ranitidine
90. Reversible neutropenia and thrombocytopenia during famotidine treatment
91. Reversible hematologic suppression during ranitidine therapy
92. Immune-mediated thrombocytopenia associated with ranitidine therapy
93. Thrombocytopenia associated with famotidine in a hemophiliac
94. Possible famotidine-induced thrombocytopenia
95. Possible famotidine-induced thrombocytopenia
96. Amiodarone-induced thrombocytopenia
97. Amrinone-associated thrombocytopenia: Pharmacokinetic analysis
98. Amrinone-induced thrombocytopenia
99. Thrombocytopenia due to sulfonamide cross-sensitivity
100. Metabolite-specific (IgG) and drug-specific antibodies (IgG, IgM) in two cases of trimethoprim/sulfamethoxazole-induced immune thrombocytopenia
101. Drug-induced post-surgical haemorrhage resulting from trimethoprim/sulfamethoxazole. A case-report
102. Amphotericin-B-induced thrombocytopenia
103. Amphotericin-B related thrombocytopenia
104. Vancomycin-dependent antibodies associated with thrombocytopenia and refractoriness to platelet transfusion in patients with thrombocytopenia induced by vancomycin
105. Thrombocytopenia with induced by vancomycin-dependent antibodies
106. Thrombocytopenia with sodium cephalothin therapy
107. Isolated severe thrombocytopenia and bleeding caused by piperacillin
108. Methicillin-associated thrombocytopenia
109. Ampicillin and hematologic effects
110. Thrombocytopenia during treatment with ampicillin
111. Intravenous immunologlobulin followed by platelet transfusion in the acute treatment of trimethoprim/sulfamethoxazole-induced thrombocytopenia
112. Immune thrombocytopenia induced by contrimazole
113. Acute thrombocytopenic purpura in relation to the use of drugs
114. Acute thrombocytopenic purpura associated with 'septrin'
115. Thrombocytopenia following administration of 'septrin'
116. Thrombocytopenia and agranulocytosis following 'septrin'
117. Severe thrombocytopenia-hemorrhage due to trimethoprim/sulfamethoxazole. A case report
118. Immune thrombocytopenia caused by piperacillin/tazobactam
119. Thrombocytopenia due to vancomycin
120. Thrombocytopenic purpura following the use of digitoxin
121. Digoxin-associated thrombocytopenia
122. Thrombocytopenia due to digoxin. Demonstration of antibody and mechanism of action
123. Thrombocytopenia following sustained-release procainamide
124. Idiopathic thrombocytopenic purpura
125. Thrombocytopenia induced by angiotensin converting enzyme inhibitors
126. Captopril associated isolated thrombocytopenia